| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study.
|
Blood
|
2015
|
1.78
|
|
2
|
Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II.
|
Mol Genet Metab
|
2014
|
0.88
|
|
3
|
Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment.
|
Mol Genet Metab
|
2015
|
0.87
|
|
4
|
Unexpected coronary artery findings in mucopolysaccharidosis. Report of four cases and literature review.
|
Cardiovasc Pathol
|
2014
|
0.82
|
|
5
|
Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI.
|
J Pediatr Rehabil Med
|
2014
|
0.81
|
|
6
|
Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome.
|
Mol Genet Metab
|
2013
|
0.81
|
|
7
|
Gene therapy for neurologic manifestations of mucopolysaccharidoses.
|
Expert Opin Drug Deliv
|
2014
|
0.79
|
|
8
|
Long-Term Cognitive and Functional Outcomes in Children with Mucopolysaccharidosis (MPS)-IH (Hurler Syndrome) Treated with Hematopoietic Cell Transplantation.
|
JIMD Rep
|
2016
|
0.78
|
|
9
|
Mucopolysaccharidosis (MPS) Physical Symptom Score: Development, Reliability, and Validity.
|
JIMD Rep
|
2015
|
0.78
|
|
10
|
Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II.
|
Mol Genet Metab Rep
|
2017
|
0.77
|
|
11
|
Standardization of α-L-iduronidase enzyme assay with Michaelis-Menten kinetics.
|
Mol Genet Metab
|
2013
|
0.77
|
|
12
|
A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II.
|
Mol Genet Metab Rep
|
2016
|
0.76
|
|
13
|
Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VI.
|
J Pediatr Rehabil Med
|
2014
|
0.75
|